As the U.S. is seeking to sever ties with some Chinese biotech players, a bipartisan group of lawmakers on Tuesday called on the Biden administration to ramp up scrutiny of hundreds of clinical trials conducted by U.S. drug companies with the Chinese military, citing the risk of intellectual property theft, as the nations compete on biotechnology.
